期刊文献+

HPLC法测定酒石酸溴莫尼定滴眼液的含量 被引量:2

Determining the content of Brimonidine Tartrate Eye Drops by HPLC
下载PDF
导出
摘要 目的建立用高效液相色谱法测定酒石酸溴莫尼定滴眼液含量的方法。方法采用AgilentC18柱。以磷酸盐缓冲液(取磷酸二氢钠7.8g,十二烷基磺酸钠0.41g与三乙胺1.0mL,加水至1000mL,摇匀)-乙腈(3:1)为流动相;检测波长为245nm;流速为1.0mL·min^-1。结果酒石酸溴莫尼定浓度在5~50μg·mL^-1范围内与峰面积呈良好的线性关系(r=0.9999);最低检测限为0.10ng;平均回收率为99.93%,RSD为0.308%。结论此法可用于测定酒石酸溴莫尼定的含量。 OBJECTIVE To establish an HPLC method for the determination of brimonidine tartrate in Brimonidine Tartrate Eye Drops. METHODS Analysised by RP--HPLC,an agilent C18 column was used; A mixture of acetonitrile--phosphate buffer solution(sodium dihydrogen phosphate 7.8g, sodium laurye sulfonate 0.41g and triethylamine 1mL, dilute to 1000mL with water)(3 : 1)was used as the mobile phase. The detection wavelength was 245nm The flow rate was 1.0mL · min^-1. RESULTS The detection limit was 0.10ng(245nm). The standard curve was linear in the range of 5 to 50μg · mL^-1 ( r =0. 9999). The average recovery was 99.93% and RSD was 0. 308%. CONCLUSION The method was suitable for determining the content of Brimonidine Tartrate Eye Drops.
出处 《齐鲁药事》 2008年第10期592-593,共2页 qilu pharmaceutical affairs
关键词 高效液相色谱法 酒石酸溴莫尼定滴眼液 含量测定 HPLC Brimonidine Tartrate Eye Drops determination
  • 相关文献

参考文献3

二级参考文献13

  • 1王勇,陈茂盛,叶应嘉,李璟,唐亮,喻长泰.沐欣滴眼液预防白内障超声乳化术后高眼压的临床观察[J].国际眼科杂志,2006,6(3):678-679. 被引量:2
  • 2张翠莲.酒石酸溴莫尼定[J].青海新闻网,2001-5:21.
  • 3Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial [J]. J Ocul Pharmacol, 2000, 16(1): 3-18.
  • 4Karamanos NK, Lamari F, Katsimpris J, et al. Development of an HPLC method for determining the alpha 2-adrenergic receptor agonist briominidine in blood serum and aqueous of the eye [J]. Biomed Chromatogr. 1999, 13: 86-88.
  • 5Toris CB. Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes.Arch Ophthalmol,1995:113 (12):1514-1517
  • 6Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.Drugs Aging, 1998:12(3):225-241
  • 7Walters TR. Development and use of brimonidine in trearing acute and chronic elevations of intraocular pressure: a review of safely, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996:41 (Snppl 1 ):19- 26
  • 8Schuman JS. Clinical experience wilh brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.Surv Ophthalmol ,1996:41 (Suppl 1 ):27-37
  • 9Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group Ⅲ.Surv Ophthalmol, 1996,41 (Suppl 1 ): 39-47
  • 10赵军阳.Brimonidine──青光眼药物的最新进展[J].国外医学(眼科学分册),1997,21(5):290-295. 被引量:5

共引文献7

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部